These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16679946)

  • 21. Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy.
    Pearson HA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):160-2. PubMed ID: 17356394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.
    Osborne RH; De Abreu Lourenço R; Dalton A; Houltram J; Dowton D; Joshua DE; Lindeman R; Ho PJ
    Value Health; 2007; 10(6):451-6. PubMed ID: 17970927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine.
    Anderson LJ; Westwood MA; Prescott E; Walker JM; Pennell DJ; Wonke B
    Acta Haematol; 2006; 115(1-2):106-8. PubMed ID: 16424659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
    Thuret I; Hacini M; Pégourié-Bandelier B; Gardembas-Pain M; Bisot-Locard S; Merlat-Guitard A; Bachir D
    Hematology; 2009 Dec; 14(6):315-22. PubMed ID: 19941737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat.
    Najafzadeh H; Jalali MR; Morovvati H; Taravati F
    J Med Toxicol; 2010 Mar; 6(1):22-6. PubMed ID: 20182837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal administration of deferoxamine to iron overloaded patients.
    Gordon GS; Ambruso DR; Robinson WA; Githens JH
    Am J Med Sci; 1989 May; 297(5):280-4. PubMed ID: 2640419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral central serous retinopathy in a patient with paroxysmal nocturnal hemoglobinuria treated with deferoxamine.
    Vahdani K; Makrygiannis G; Kaneshyogan H; Sian IS; Giasin O
    Eur J Ophthalmol; 2016 Nov; 26(6):e152-e154. PubMed ID: 27445073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desferrioxamine treatment of iron overload secondary to RH isoimmunization and intrauterine transfusion in a newborn infant.
    Yalaz M; Bilgin BS; Köroğlu OA; Ay Y; Arıkan C; Sagol S; Akısü M; Kültürsay N
    Eur J Pediatr; 2011 Nov; 170(11):1457-60. PubMed ID: 21735053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods.
    Yeatts SD; Palesch YY; Moy CS; Selim M
    Neurocrit Care; 2013 Oct; 19(2):257-66. PubMed ID: 23943316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a new method of administration of the iron chelating agent deferoxamine.
    Borgna-Pignatti C; Cohen A
    J Pediatr; 1997 Jan; 130(1):86-8. PubMed ID: 9003855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.
    Styles LA; Vichinsky EP
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):42-5. PubMed ID: 8556369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of myocardial and hepatic iron loading by MRI T2* in multi-transfused patients with repeated blood loss as compared to thalassaemia major patients and controls.
    Mavrogeni S
    Blood Transfus; 2011 Jul; 9(3):343-5. PubMed ID: 21627929
    [No Abstract]   [Full Text] [Related]  

  • 36. Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature.
    Georgakopoulos CD; Tsapardoni F; Kostopoulou EV; Makri OE
    BMC Ophthalmol; 2018 Sep; 18(1):246. PubMed ID: 30208862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desferrioxamine-related ocular toxicity: a case report.
    Simon S; Athanasiov PA; Jain R; Raymond G; Gilhotra JS
    Indian J Ophthalmol; 2012 Jul; 60(4):315-7. PubMed ID: 22824603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of iron overload and its treatment on quality of life: results from a literature review.
    Abetz L; Baladi JF; Jones P; Rofail D
    Health Qual Life Outcomes; 2006 Sep; 4():73. PubMed ID: 17007645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Iron intoxication--poisoning with easily accessible medicines].
    Galmén K; Höjer J
    Lakartidningen; 2014 Sep 17-23; 111(38):1576-7. PubMed ID: 25606656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.